Abstract
Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient
Highlights
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the world
Randomized clinical trials have shown that second-line chemotherapy in NSCLC patients who failed or relapsed first-line therapy, can offer modest and marginal survival benefits at the cost of considerable toxicity
It should be stressed that only single-agent therapies have been approved and are recommended for clinical use in this clinical setting
Summary
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality in the world. Randomized clinical trials have shown that second-line chemotherapy in NSCLC patients who failed or relapsed first-line therapy, can offer modest and marginal survival benefits at the cost of considerable toxicity. Treatment options available for previously treated advanced-metastatic NSCLC are single agent docetaxel, pemetrexed, and epidermal growth factor receptor inhibitors (erlotinib and gefitinib) [6]. It should be stressed that only single-agent therapies have been approved and are recommended for clinical use in this clinical setting.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call